These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 20580108)

  • 1. Replacement therapy for iron deficiency improves exercise capacity and quality of life in patients with cyanotic congenital heart disease and/or the Eisenmenger syndrome.
    Tay EL; Peset A; Papaphylactou M; Inuzuka R; Alonso-Gonzalez R; Giannakoulas G; Tzifa A; Goletto S; Broberg C; Dimopoulos K; Gatzoulis MA
    Int J Cardiol; 2011 Sep; 151(3):307-12. PubMed ID: 20580108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exercise performance and quality of life is more impaired in Eisenmenger syndrome than in complex cyanotic congenital heart disease with pulmonary stenosis.
    Müller J; Hess J; Hager A
    Int J Cardiol; 2011 Jul; 150(2):177-81. PubMed ID: 20439122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life and functional capacity can be improved in patients with Eisenmenger syndrome with oral sildenafil therapy.
    Tay EL; Papaphylactou M; Diller GP; Alonso-Gonzalez R; Inuzuka R; Giannakoulas G; Harries C; Wort SJ; Swan L; Dimopoulos K; Gatzoulis MA
    Int J Cardiol; 2011 Jun; 149(3):372-6. PubMed ID: 20304507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood viscosity and its relationship to iron deficiency, symptoms, and exercise capacity in adults with cyanotic congenital heart disease.
    Broberg CS; Bax BE; Okonko DO; Rampling MW; Bayne S; Harries C; Davidson SJ; Uebing A; Khan AA; Thein S; Gibbs JS; Burman J; Gatzoulis MA
    J Am Coll Cardiol; 2006 Jul; 48(2):356-65. PubMed ID: 16843187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial.
    Okonko DO; Grzeslo A; Witkowski T; Mandal AK; Slater RM; Roughton M; Foldes G; Thum T; Majda J; Banasiak W; Missouris CG; Poole-Wilson PA; Anker SD; Ponikowski P
    J Am Coll Cardiol; 2008 Jan; 51(2):103-12. PubMed ID: 18191732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The BNP concentrations and exercise capacity assessment with cardiopulmonary stress test in cyanotic adult patients with congenital heart diseases.
    Trojnarska O; Gwizdala A; Katarzynski S; Katarzynska A; Oko-Sarnowska Z; Grajek S; Kramer L
    Int J Cardiol; 2010 Mar; 139(3):241-7. PubMed ID: 19042041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of exercise capacity with cardiopulmonary exercise test and B-type natriuretic peptide in adults with congenital heart disease.
    Trojnarska O; Gwizdała A; Katarzyński S; Katarzyńska A; Szyszka A; Lanocha M; Grajek S; Kramer L
    Cardiol J; 2009; 16(2):133-41. PubMed ID: 19387960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without Down's syndrome.
    Duffels MG; Vis JC; van Loon RL; Nieuwkerk PT; van Dijk AP; Hoendermis ES; de Bruin-Bon RH; Bouma BJ; Bresser P; Berger RM; Mulder BJ
    Am J Cardiol; 2009 May; 103(9):1309-15. PubMed ID: 19406277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: a pilot study.
    Viethen T; Gerhardt F; Dumitrescu D; Knoop-Busch S; ten Freyhaus H; Rudolph TK; Baldus S; Rosenkranz S
    Int J Cardiol; 2014 Aug; 175(2):233-9. PubMed ID: 24880481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-estimated physical functioning poorly predicts actual exercise capacity in adolescents and adults with congenital heart disease.
    Gratz A; Hess J; Hager A
    Eur Heart J; 2009 Feb; 30(4):497-504. PubMed ID: 19066211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
    Toblli JE; Lombraña A; Duarte P; Di Gennaro F
    J Am Coll Cardiol; 2007 Oct; 50(17):1657-65. PubMed ID: 17950147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure.
    Jankowska EA; Rozentryt P; Witkowska A; Nowak J; Hartmann O; Ponikowska B; Borodulin-Nadzieja L; von Haehling S; Doehner W; Banasiak W; Polonski L; Filippatos G; Anker SD; Ponikowski P
    J Card Fail; 2011 Nov; 17(11):899-906. PubMed ID: 22041326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial.
    Van Wyck DB; Mangione A; Morrison J; Hadley PE; Jehle JA; Goodnough LT
    Transfusion; 2009 Dec; 49(12):2719-28. PubMed ID: 19682342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of bosentan in adults with simple and complex Eisenmenger's syndrome.
    Williams R; Houser L; Miner P; Aboulhosn J
    Congenit Heart Dis; 2012; 7(1):12-5. PubMed ID: 22188797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dose-effect of the administration of ferrous fumarate in aged persons with iron deficiency].
    Lares-Asseff I; Pérez MG; López MC; Romero L; Camacho GA; Toledo A; Guillé AJ; Trujillo F; Juárez H; Flores J
    Rev Gastroenterol Mex; 1999; 64(4):159-66. PubMed ID: 10851577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications.
    Bailie GR
    Arzneimittelforschung; 2010; 60(6a):386-98. PubMed ID: 20648930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelin receptor antagonists improve exercise tolerance and oxygen saturations in patients with Eisenmenger syndrome and congenital heart defects.
    Mehta PK; Simpson L; Lee EK; Lyle TA; McConnell ME; Book WM
    Tex Heart Inst J; 2008; 35(3):256-61. PubMed ID: 18941642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reference values for exercise limitations among adults with congenital heart disease. Relation to activities of daily life--single centre experience and review of published data.
    Kempny A; Dimopoulos K; Uebing A; Moceri P; Swan L; Gatzoulis MA; Diller GP
    Eur Heart J; 2012 Jun; 33(11):1386-96. PubMed ID: 22199119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral sildenafil treatment for Eisenmenger syndrome: a prospective, open-label, multicentre study.
    Zhang ZN; Jiang X; Zhang R; Li XL; Wu BX; Zhao QH; Wang Y; Dai LZ; Pan L; Gomberg-Maitland M; Jing ZC
    Heart; 2011 Nov; 97(22):1876-81. PubMed ID: 21948962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are we giving too much iron? Low-dose iron therapy is effective in octogenarians.
    Rimon E; Kagansky N; Kagansky M; Mechnick L; Mashiah T; Namir M; Levy S
    Am J Med; 2005 Oct; 118(10):1142-7. PubMed ID: 16194646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.